Is Whole Genome Sequencing Worth It at 40

Message us and we will tell you which of the three you are, or call 020 3951 3429.

When to get help today

This is a planning decision and not an urgent one. If you have chest pain, breathlessness at rest, or you lose consciousness without warning, call 999 or go to your nearest emergency department today.

Sudden cardiac death before 40 in a close relative is the one thing here that should be seen quickly. Say so when you enquire and the cardiology assessment comes first.

The three answers

There are only three answers to this question, and most people can place themselves in the right one in about two minutes. The three are set out below with the reasoning behind each, so you can decide before you speak to anybody.

Yes means the file will change a decision you are going to make anyway. Not yet means it probably will one day and today is not that day. No means it will change nothing for you and you should keep your money.

We would rather tell you the third than sell you the first, because a clinic that will not talk you out of a purchase is a clinic whose recommendation is worth nothing.

Yes, if any of this is true

You take several medicines, or one has already disagreed with you. In PREPARE, 6,944 patients across seven countries, clinically relevant adverse drug reactions fell from 28.6% to 21.5% when prescribing followed a pharmacogenomic report, an odds ratio of 0.70, Swen and colleagues, The Lancet, 2023. The more prescriptions ahead of you, the more times that report is used. Van Driest and colleagues found 91% of 9,589 people genotyped carried at least one actionable variant across five gene and drug pairs, Clinical Pharmacology and Therapeutics, 2014.

Heart disease or sudden death appeared young in your family. The inherited cardiomyopathies, the arrhythmia syndromes and the aortopathies are all on the ACMG secondary findings list at version 3.3, Genetics in Medicine, 2025, and all are managed with surveillance that works better the earlier it starts.

The same cancer appeared more than once on one side of your family, or any cancer appeared young. Hereditary breast and ovarian cancer and Lynch syndrome are on the same list, and both change screening intervals rather than only outcomes.

A family decision is coming. Planning children, or a relative has just been diagnosed and everyone is asking what it means for them. A result in hand before the decision is worth more than the same result afterwards.

You are the person your family will ask. A finding in you is information about your parents, your brothers and sisters and your children, and somebody usually goes first.

Message us about which of these describes you

Not yet, if this describes you

You are well, you take nothing regular, nothing in your family appeared young, and nothing is being decided this year. That is the commonest position of the people who read a page like this, and it is a position in which waiting costs very little.

Your genome does not change, so nothing is lost by waiting. What is lost is the years of surveillance a finding would have started, which is the only real argument for doing it now rather than at 45. That argument is honest and it is not overwhelming.

If you are in this group and you still want it, buy it knowing you are buying reassurance and a file for later rather than an answer to a question you currently have.

No, and here is who we turn away

Anyone with a symptom now. Get the symptom diagnosed first, by whatever route is quickest. Sequencing is a slow and poor way to work out what is wrong today, and starting there delays the answer rather than producing it.

Anyone whose family already carries a known variant. Targeted testing for that exact variant, through the service already looking after the family, is faster, cheaper and gives a cleaner answer. We will say so and point you there.

Anyone who would not act. If you would not change a screening interval, take a medicine or tell a relative, the file changes nothing. A general health check on its own does not lower mortality, across 251,891 people in the 2019 Cochrane review, and the reason is that information nobody acts on does nothing.

Anyone buying it for a child without a clinical reason. We do not sequence children for adult onset conditions on request.

Anyone for whom an uncertain result would be intolerable. A large share of what sequencing finds is a variant of uncertain significance, which is neither a diagnosis nor an all clear. Say so in the first conversation.

Why this question arrives at 40 and not at 30

Two things usually happen around this age, and neither of them is a statistic. They are the reason the question arrives when it does, and they are also the reason the answer is more often yes at 40 than at 30.

The first prescription that will last for decades arrives. Blood pressure, cholesterol, something for mood or sleep. That is the point at which a pharmacogenomic report stops being interesting and starts being used, because the value of it is in every prescription after it rather than in the report itself.

And a parent is diagnosed with something. That is when a family history becomes a question rather than a fact, and when the person asking is usually the one in their forties.

What the money buys, and where it sits in the market

Comprehensive private imaging programmes in London publish figures above £32,000. Longevity memberships have been reported at £25,000 a year, with press coverage of a £54,000 bracket. Private hospital executive tiers run £3,500 to £8,000 and Cleveland Clinic London publishes £5,500 for its executive assessment. All read September 2026.

Against that, Genome is £4,995, Genome and Medicines is £9,995, and Family Genome is £29,995 for four people. The difference in kind is that an assessment is bought again every year and a genome is bought once and read again every year.

At 40, with a long prescribing life ahead, Genome and Medicines is the tier that earns its price, because the pharmacogenomic report is used every time somebody writes you a prescription for the rest of your life.

What you can do before you decide

Answer four questions on paper before you speak to anybody, ours included. They are the questions a good counsellor would put to you in the first ten minutes, and having the answers ready makes that conversation shorter and better.

What would I do differently if the answer were bad. What would I do differently if the answer were normal. Who else does this result belong to. Would I still want to know in five years if nothing could be done.

Then write a three generation family history with ages and causes. Anything before 50 carries far more weight than anything after 70. That page is useful to every doctor you will ever see and it costs nothing, and it is the single thing most likely to change our advice about whether to proceed.

What we would do

One. A conversation with a registered genetic counsellor, at no charge, which may end with us telling you not to proceed or to wait a few years. Nothing is taken and nothing is committed on that call.

Two. Saliva at home or a blood draw in Marylebone, sequenced at 30x in a laboratory accredited to ISO 15189.

Three. The result read with a doctor, written into your record, and re read every year for life on Genome and Medicines.

Book Genome and Medicines

Message us to book the first conversation

Questions people ask

Is whole genome sequencing worth it at 40? Yes if you take several medicines, if heart disease or cancer appeared young in your family, or if a family decision is coming. Not yet if you are well with no family history. No if you would not act on a result. Around 6% carry a finding that changes management, on 3,972 exomes read against ACMG SF v3.3, Genetics in Medicine, 2025.

Which tier should someone of 40 buy? Usually Genome and Medicines at £9,995, because the pharmacogenomic report is used at every prescription for the rest of your life and the file is re read every year. Genome at £4,995 is the right answer where medicines are not the question.

Am I too young at 30? Not too young, and often too early. Nothing is lost by waiting, because your genome does not change. What is lost is the extra years of surveillance a finding would have started, which is a real argument and not a large one.

Is 50 or 60 too late? No. The pharmacogenomic half becomes more useful with age because prescribing increases, and a cancer or cardiac finding still changes screening. What changes is that some of the preventive value has already passed.

What if I am healthy with no family history? Then you are buying reassurance and a file for later. That is a legitimate purchase and it should be made knowingly rather than sold to you as an answer to a question you do not have.

Will it tell me how long I will live? No. Nothing in a sequence carries that. It reads a defined set of genes for findings that change what a doctor does, and it is silent about the mixture of environment, behaviour and chance that decides most of what happens to most people. Any provider suggesting otherwise is overstating what sequencing does.

Do I have to decide about family members now? No. A finding in you is information about your relatives, and the counsellor helps you decide who to tell and when. Family Genome at £29,995 covers four people where a family wants to do it together.

What happens after the first conversation? Nothing automatically. The counsellor's first conversation is not charged and does not commit you to a sample, and a good number of them end with a recommendation to wait or to do something simpler first. If you go ahead, the sample is taken at home or in Marylebone and the results appointment is booked when the report lands.

Message us before you decide, or call 020 3951 3429.

This page is information and not a diagnosis. Sequencing does not replace examination, history or blood work, and no result guarantees an outcome. Prices are published starting figures and are confirmed before anything is taken. If you are unwell today, see a doctor today. In an emergency call 999.

References

Swen JJ, van der Wouden CH, Manson LE, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions. The Lancet, 2023;401(10374):347-356. 10.1016/S0140-6736(22)01841-4

Van Driest SL, et al. Clinical Pharmacology and Therapeutics, 2014;95(4):423-431.

Krogsbøll LT, et al. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database of Systematic Reviews, 2019. 10.1002/14651858.CD009009.pub3

American College of Medical Genetics and Genomics. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, ACMG SF v3.3. Genetics in Medicine, 2025.

European Society of Cardiology. Clinical consensus statement on polygenic risk scores in cardiovascular disease. European Heart Journal, 2025.

Pereira NL, Farkouh ME, So D, et al. JAMA, 2020;324(8):761-771. PMID 32840598.

Clinical Pharmacogenetics Implementation Consortium. Published gene and drug guidelines, cpicpgx.org, read 8 September 2026.

ISO 15189:2022. Medical laboratories, requirements for quality and competence. International Organization for Standardization.

Cleveland Clinic London. Published executive health assessment price, read September 2026.

The London Genetics Centre. Published whole genome sequencing price, thelondongeneticscentre.com, read 8 September 2026.